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DESCRIPTION

Gadolinium-b ased contrast agents (GBCAs) are
widely used in imaging today. GBCAs are used in
25% of all MRI examinations and, at times, are
used to facilitate the fluoroscopic-guided interventional procedures associated with chronic
pain. Gadolinium, Gd3+, is the most paramagnetic element practically available. GBCAs
are ideal for enhancing MRI. Gadolinium is a
toxic element. Linear or macrocyclic chelating
compounds (ie, polyaminocarboxylic acid
formulations) reduce the toxicity of the metal
and increase its elimination. Following intravenous injection, GBCAs are distributed in the

blood and extracellular tissue and are rapidly
eliminated by the kidneys. The intravenous
application of GBCAs has been considered relatively safe and benign. However, the impact of
GBCAs on human health and their mechanism of
toxicity is mostly unknown.1 2
GBCAs are also used as an alternative to iodinated contrast agents for neuraxial procedures
routinely performed by interventional pain
physicians. 3 A patient with chronic pain with
shellfish allergy inadvertently received 2 mL
of gadobutrol (a type of GBCA) intrathecally
during lumbar epidural steroid injection, which
was confirmed fluoroscopically (figure 1A,B).

Figure 1 (A) Anteroposterior fluoroscopic view of the lumbar spine shows flat glass-like appearance of gadobutrol
contrast (white arrow) as opposed to a patchy honeycomb appearance in the epidural space with 18-gauge Quincke
spinal needle at the L5–S1 level (blue arrowhead). (B) Lateral fluoroscopic view of the lumbar spine shows gadobutrol
contrast outlining the thecal sac (white arrow) and the tip of 18-gauge Quincke spinal needle in the intrathecal space
(blue arrowhead). AP, anteroposterior.
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Figure 2 (A) Non-contrast CT scan of the coronal section of brain shows diffuse large-volume hyperattenuation
throughout the subarachnoid spaces in the quadrigeminal cisterns, interpeduncular cistern, prepontine cistern and
cisterna magna with sparing of the vertex. (B) The sagittal section on CT scan shows hyperattenuation of Sylvian
cisterns, ambient cisterns, quadrigeminal cisterns and interpeduncular cistern.
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Patient’s perspective
I had this procedure multiple times in the past, but this time it
felt different. I started feeling sick to my stomach and developed
a bad headache. I thought I was having a stroke. I was sweating
a lot and then I started seeing a lot of colours. I remember
hearing a lot of noises. I woke up with the intense feeling of
dryness in my mouth and a gagging sensation. I felt nauseous
and still had a bad headache. I could barely open my eyes as
the lights were blinding me and I had some sort of cream in my
eyes. My hands were tied, which scared me. I had a bad itch in
my throat, but I could not do anything. I also felt very cold and
started shivering. I vaguely remember a shadow coming close
to me and trying to talk to me. I could not understand a word.
I started feeling sleepy again. I was very very scared. I woke up
again and my room was dark. I again had a gagging sensation
and intense pain in my throat. I again remember someone
coming close to me, and I thought that they would hurt me. I
started to fight but my hands were tied. I started kicking and
then I heard my wife’s voice. I could barely understand what she
and the other person was saying. After few minutes, I could see
their faces. I wanted to yell and scream at her. I was very angry.
Then the other person told me that I had a bad reaction in the
pain clinic, and I was in intensive care unit for 2 days. I could
not believe. I thought I was still in the clinic. I wanted them to
help me with the gagging sensation in my throat. They made me
sit and I could see a lot of wires. They gave me a paper to write
but I could barely hold the pen. I pointed out towards my throat
and I was extremely angry. I had lot of pain in my throat, but I
could see more clearly and hear more noises from outside my
cabin. My wife was with me. She was crying and told me that I
almost died. At that point the only thing I cared was the dryness
in my mouth and the gagging sensation. I also started feeling
nauseous and my back and head stated hurting. After a few
minutes, more people entered the room, and they removed a big
tube from my stomach. I coughed violently and stated spitting.
I couldn’t talk at first. I again got scared. I thought that I had a
stroke, and my voice is gone. My mouth was very dry and crusty;
I had a bad headache and I felt very very tired. I took some sips
and chewed on a wet sponge. After a while I could speak, and
I asked for my pain doctor. My wife told me that I was in coma
for 2 days and I almost died. I was still angry at her for leaving
me like this. I tried to move my arms and my legs to make sure
they are working. The pain doctor came in after some time and
explained to me what happened. I remember the pain doctor
coming to see me in the cabin. He also explained to me what
happened. I was relieved that I did not have a stroke.
Within 30 min of injection, the patient reported severe headache, confusion and aphasia, along with generalised tonic–
clonic seizures. The patient was emergently intubated. Brain
imaging performed within 2 hours of intrathecal injection
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was notable for contrast diffusely in the subarachnoid
space. A diffuse large-v olume hyperattenuation was present
throughout the subarachnoid space on a CT scan of the brain
(figure 2A). There was hyperattenuation of the Sylvian,
ambient, quadrigeminal and interpeduncular cisterns by CT
imaging (figure 2B).
The patient made a full recovery within 72 hours. GBCAs
have varying molar concentrations, and similar volume
limits cannot be used across different GBCAs. Moreover, the
safe dose limit of 2.5 μmol/g brain tissue, based on animal
studies, fails to correlate with humans as humans may be
more sensitive to intrathecal GBCA than animals. 4 5 The
authors conclude that GBCAs may cause catastrophic neurological injury, and proceduralists should exercise caution
when using GBCAs during interlaminar epidural steroid
injections.

Learning points
►► Gadolinium-based contrast agents (GBCAs) when injected

intrathecally, an off-label use, may lead to severe neurological
sequelae; caution should be exercised during procedures
employing these agents.
►► Physicians should be aware of ‘gadolinium encephalopathy’ as a
clinical entity. A treatment algorithm should be in the facility for
inadvertent intrathecal injection of GBCAs.
►► Iodinated contrast agents can be used in patients with shellfish
allergy.
Contributors GC: drafted the manuscript and performed the literature search and
proofreading. AU: treated the patient, was involved in clinical care and defined the
intellectual content of the manuscript.
Funding The authors have not declared a specific grant for this research from any
funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.
ORCID iD
Gaurav Chauhan http://orcid.org/0000-0003-4468-1808

REFERENCES

1 Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including
gadolinium deposition. J Magn Reson Imaging 2009;30:1259–67.
2 Malikova H, Holesta M. Gadolinium contrast agents – are they really safe? J Vasc
Access 2017;28:1–7.
3 Popescu A, Patel J, McCormick ZL, et al. Fact finders for patient safety: are gadolinium-
based contrast media safe alternatives to iodinated contrast agents for the safe
performance of spinal injection procedures? Pain Med 2018;19:2089–90.
4 Park K-W, Im S-B, Kim B-T, et al. Neurotoxic manifestations of an overdose intrathecal
injection of gadopentetate dimeglumine. J Korean Med Sci 2010;25:505–8.
5 Provenzano DA, Pellis Z, DeRiggi L. Fatal gadolinium-induced encephalopathy following
accidental intrathecal administration: a case report and a comprehensive evidence-
based review. Reg Anesth Pain Med 2019;44:721–9.

Chauhan G, Upadhyay A. BMJ Case Rep 2021;14:e241372. doi:10.1136/bcr-2020-241372

BMJ Case Rep: first published as 10.1136/bcr-2020-241372 on 26 January 2021. Downloaded from http://casereports.bmj.com/ on February 23, 2021 at Henry Ford Hospital. Protected by
copyright.

Images in…

Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit
https://www.bmj.com/company/products-services/rights-and-licensing/permissions/
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.
Become a Fellow of BMJ Case Reports today and you can:
►► Submit as many cases as you like
►► Enjoy fast sympathetic peer review and rapid publication of accepted articles
►► Access all the published articles
►► Re-use any of the published material for personal use and teaching without further permission
Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.
Visit casereports.bmj.com for more articles like this and to become a Fellow

Chauhan G, Upadhyay A. BMJ Case Rep 2021;14:e241372. doi:10.1136/bcr-2020-241372

3

BMJ Case Rep: first published as 10.1136/bcr-2020-241372 on 26 January 2021. Downloaded from http://casereports.bmj.com/ on February 23, 2021 at Henry Ford Hospital. Protected by
copyright.

Images in…

